Sustained activation of the Aryl hydrocarbon Receptor transcription factor promotes resistance to BRAF-inhibitors in melanoma
Resistance to BRAF inhibitors limits their clinical benefit in melanoma patients. Here, the authors show that the Aryl hydrocarbon Receptor (AhR) is a key mediator of resistant genes and use resveratrol, an AhR antagonist, to revert resistance in melanoma bearing mice.
Guardado en:
Autores principales: | Sébastien Corre, Nina Tardif, Nicolas Mouchet, Héloïse M. Leclair, Lise Boussemart, Arthur Gautron, Laura Bachelot, Anthony Perrot, Anatoly Soshilov, Aljosja Rogiers, Florian Rambow, Erwan Dumontet, Karin Tarte, Alban Bessede, Gilles J. Guillemin, Jean-Christophe Marine, Michael S. Denison, David Gilot, Marie-Dominique Galibert |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e059e48b1f30450aba786bdcd533d146 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Sustained SREBP-1-dependent lipogenesis as a key mediator of resistance to BRAF-targeted therapy
por: Ali Talebi, et al.
Publicado: (2018) -
IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Hima Patel, et al.
Publicado: (2021) -
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
por: Maria Gonzalez-Cao, et al.
Publicado: (2021) -
Nucleophilic arylation with tetraarylphosphonium salts
por: Zuyong Deng, et al.
Publicado: (2016) -
Facilitating the transmetalation step with aryl-zincates in nickel-catalyzed enantioselective arylation of secondary benzylic halides
por: Weichen Huang, et al.
Publicado: (2019)